Cipla receives final approval for generic anti-HIV drug

Global pharma major Cipla has received final approval from USFDA to market a generic equivalent of Tenofovir Disoproxil Fumarate 300mg tablets. The drug will be made available for commercial shipment in the US immediately.

Tenofovir Disoproxil Fumarate is an AB-rated generic version of Gilead Sciences' Viread tablets. The drug prescribed in combination with other anti-retroviral (ARV) agents for the treatment of HIV-1 in patients above the age of 12 years. This drug will be a significant addition to Cipla's growing ARV portfolio for the US market.

The US sales for Viread 300mg tablets stood at approximately US$725 million on a YoY basis as on November 2017, reported IMS Health.

Meanwhile, the stock of Cipla was quoting Rs. 625.30 per share, up by per cent in the morning session on Monday, while BSE Sensex was at 36,358.16, up 307.72 points or 0.85 per cent.